A concentrated grape-seed preparation with broad coverage but small effects. Blood pressure, resting heart rate, blood cholesterol and fasting blood sugar all shift favorably, mainly in people starting with raised values. Digestive upset is the recurring complaint; falling blood iron at very high intakes and widespread peanut-skin substitution in commercial products make product quality the larger practical concern. (Full Review)

Protocol

Standard dose

100–400 mg daily

Trials producing blood-pressure effects used 150–300 mg daily

Standardization matters more than dose

At least 95% oligomeric proanthocyanidins

Products differ several-fold in proanthocyanidin content at identical label weights

Best time of day

With a meal, morning or evening

No circadian dependence demonstrated; once daily is what almost all trials used

Time to effect

Blood pressure

4 weeks

The point at which pooled trials first detected change

Blood lipids

4–12 weeks

Total and LDL cholesterol and triglycerides; panel repeated at 12 weeks

Retinal and menopausal symptoms

8 weeks – 12 months

The longest endpoints; retinal hard exudates ran the full 12 months

Benefits

High: Lower blood pressure; lower total and LDL cholesterol; lower fasting blood glucose; lower resting heart rate

Medium: Reduced retinal hard exudates in non-proliferative diabetic retinopathy; reduced leg swelling during prolonged sitting; relief of menopausal physical symptoms and insomnia; improved liver fat and liver enzymes in fatty liver disease

Low: Modest weight reduction in people with obesity; lower C-reactive protein; cognitive performance

Speculative: Senescent-cell clearance and lifespan extension; reduced oxidative damage markers; suppression of bronchial cell proliferation in heavy smokers; dental enamel remineralization

Contraindications

Pregnancy and lactation at any dose

Established iron deficiency anemia (ferritin below 30 ng/mL or hemoglobin below 12 g/dL in women, 13 g/dL in men) until repleted

Documented peanut allergy, unless third-party identity testing excludes peanut skin extract

Scheduled surgery within 14 days (including dental extraction, colonoscopy with anticipated polypectomy)

Symptomatic hypotension or autonomic failure with systolic pressure persistently below 100 mmHg

Key Interactions

Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin)

Antihypertensives (amlodipine, lisinopril, losartan, hydrochlorothiazide)

Iron salts (ferrous sulfate, ferrous bisglycinate) and iron-rich meals

CYP1A2 substrates (caffeine, theophylline, duloxetine, clozapine, tizanidine)

Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen, aspirin)

Blood-pressure-lowering supplements (beetroot nitrate, magnesium, potassium, garlic extract, Pycnogenol)

Blood-thinning supplements (fish oil, vitamin E, ginkgo, nattokinase, high-dose curcumin)

Other interventions: high-dose antioxidant stacks around training blocks; chelation protocols; proton pump inhibitors (omeprazole, pantoprazole)

Risk & Side Effects

High: Gastrointestinal discomfort

Low: Headache, dizziness and itchy skin or scalp; reduced iron absorption and falling serum iron; additive hypotension with antihypertensive therapy; peanut protein exposure from adulterated product

Speculative: Increased bleeding risk with antiplatelet or anticoagulant drugs; interference with drugs cleared by CYP1A2; blunted adaptation to endurance and resistance training; unestablished safety in pregnancy and lactation

Monitoring

Marker	Target	Why
Home systolic / diastolic blood pressure	110–120 / 70–75 mmHg	Primary efficacy endpoint; also detects additive hypotension
LDL cholesterol	Below 80 mg/dL	Second efficacy endpoint; validated surrogate for cardiovascular events
Triglycerides	Below 80 mg/dL	Moves alongside cholesterol in pooled trials; sensitive to diet confounding
Fasting glucose	75–86 mg/dL	Efficacy endpoint with the most consistent pooled signal
Glycated hemoglobin	Below 5.3%	Confirms whether the fasting glucose change persists over months
High-sensitivity C-reactive protein	Below 0.8 mg/L	Inflammation endpoint, though pooled results conflict
Ferritin	50–150 ng/mL (women), 75–200 ng/mL (men)	Core safety measure; detects tannin-mediated iron depletion
Serum iron and transferrin saturation	85–130 µg/dL; 25–35%	Detects the specific signal seen at high extract intake
Hemoglobin	13.5–14.5 g/dL (women), 14.5–15.5 g/dL (men)	Confirms that any iron change has not progressed to anemia
Alanine and aspartate aminotransferase	Below 25 U/L (women), below 30 U/L (men)	General tolerance check

Cadence: Baseline before the first dose; home blood pressure repeated at four weeks; lipid, glucose and inflammation panel at twelve weeks; iron panel and complete blood count at six months, then annually.

Qualitative Assessment

Leg heaviness, ankle swelling and sock-line indentation after long seated periods, the symptom domain with the most direct trial support
Sleep continuity and night-waking frequency, particularly during the menopausal transition
Unusual bruising, gum bleeding or prolonged bleeding from minor cuts, the earliest practical sign of the theoretical platelet interaction
Nausea, abdominal discomfort or stool changes in the first two weeks, the window in which gastrointestinal intolerance appears
Cold hands and feet, exertional fatigue and reduced exercise tolerance, which can signal falling iron before ferritin is next measured
Dizziness on standing, which would indicate additive hypotension against existing medication

Grape Seed Extract for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment